CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, announced it has successfully completed its multi-year collaborative agreement with Merck & Co., Inc., which utilized AVEO’s proprietary cancer models to identify and validate essential tumor maintenance genes which are attractive targets for the development of small molecule oncology agents.
